Page 1

燃 石 医学 Burning Rock Dx Burning Rock Reports Third Quarter 2021 Financial Results November 16 , 2021 GUANGZHOU , China , Nov. 15 , 2021 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ : BNR , the " Company " or " Burning Rock " ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology , today reported financial results for the three months ended September 30 , 2021 . Business Updates Early Detection o 6 - cancer product : we have successfully signed contracts with a small number of pilot hospitals in China for the commercialization of our 6 - cancer early detection product , and will focus on customer education and contracting more hospitals . o 9 - cancer product : we expect our 9 - cancer early detection product development read - out in the first half of 2022 , with potential performance improvement over that of our 6 - cancer early detection product . • Pharma Services . o Pharma service contract backlog continues to build rapidly . The total value of new contracts we entered into during the nine months ended September 30 , 2021 amounted to RMB144 million , which is approximately 4.5 times of the new contract value signed in full - year 2020 . o Pharma projects involving our Clinical Laboratory Improvement Amendments ( CLIA ) -certified and College of American Pathologists ( CAP ) -accredited laboratory in California continue to grow . For instance , in early November , we announced further collaboration with IMPACT Therapeutics where our Guangzhou and California laboratories would provide testing services in connection with IMPACT Therapeutics ' development of its ATR inhibitor IMP9064 , which has received the Investigational New Drug ( IND ) clearance from the U.S. Food and Drug Administration ( FDA ) for the Phase I / II clinical study . Therapy Selection o Continued execution of our strategic shift towards more in - hospital testing , with industry - leading scale and growth rate . The volume of in - hospital NGS - based test kits grew 37 % year - over - year to over 11,000 tests during the third quarter of 2021 , despite the negative COVID - 19 impact in August . Third Quarter 2021 Financial Results Revenues were RMB126.6 million ( US $ 19.7 million ) for the three months ended September 30 , 2021 , representing a 2.2 % increase from RMB123.9 million for the same period in 2020 , or a 0.5 % sequential decrease from RMB127.3 million for the three months ended June 30 , 2021 . • Revenue generated from central laboratory business was RMB78.8 million ( US $ 12.2 million ) for the three months ended September 30 , 2021 , representing a 12.3 % decrease from RMB89.9 million for the same period in 2020 , primarily attributable to a decrease in the number of patients tested in the central laboratory channel to 7,808 for the three months ended September 30 , 2021 , representing a 9.7 % decrease from 8,644 for the same period in 2020 . • Revenue generated from in - hospital business was RMB43.7 million ( US $ 6.8 million ) for the three months ended September 30 , 2021 , representing a 37.9 % increase from RMB31.7 million for the same period in 2020 , driven by in - hospital testing volume growth . • Revenue generated from pharma research and development services was RMB4.1 million ( US $ 0.6 million ) for the three months ended September 30 , 2021 , representing a 79.3 % increase from RMB2.3 million for the same period in 2020 , primarily attributable to increased testing performed for our pharma customers and growth in companion diagnostics development services . Cost of revenues was RMB35.0 million ( US $ 5.4 million ) for the three months ended September 30 , 2021 , representing an 8.4 % increase from RMB32.3 million for the same period in 2020 , which was generally in line with the Company's continued business growth . Gross profit was RMB91.6 million ( US $ 14.2 million ) for the three months ended September 30 , 2021 , which was remained relatively stable compared